GOSS SEC 보고서 - Gossamer Bio, Inc.- 연례 보고, 기업 사업 설명서, 유가증권계출서

기본 통계

LEI	549300ZOC0N2W6PSFR58
CIK	1728117

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Gossamer Bio, Inc.

SEC Filings (Chronological Order)

이 페이지는 다른 곳에서 제공하는 소유권 보고서를 제외한 SEC 보고서의 전체 리스트를 시간 순으로 정리한 것입니다.

June 5, 2026	EX-99.1	Gossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes Exhibit 99.1 Gossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes San Diego, California. (June 3, 2026) – Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company” or “Gossamer”), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary a
June 5, 2026	EX-10.1	Exhibit 10.1 GOSSAMER BIO, INC., THE GUARANTORS PARTY HERETO FROM TIME TO TIME, U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Collateral Agent INDENTURE Dated as of June 4, 2026 Senior goss-20260604xexx101inde Exhibit 10.1 GOSSAMER BIO, INC., THE GUARANTORS PARTY HERETO FROM TIME TO TIME, U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Collateral Agent INDENTURE Dated as of June 4, 2026 Senior Secured First Lien Convertible Notes due 2030 i TABLE OF CONTENTS Page Article 1. Definitions ..............................
June 5, 2026	EX-10.5	Exhibit 10.5 THIS SECOND SUPPLEMENTAL INDENTURE (the “Second Supplemental Indenture”), dated as of June 4, 2026 (the “Effective Date”), is entered into by and between Gossamer Bio, Inc., a Delaware corporation (the “Company”), and Wilmington Trust, N goss-20260604xexx105seco Exhibit 10.5 THIS SECOND SUPPLEMENTAL INDENTURE (the “Second Supplemental Indenture”), dated as of June 4, 2026 (the “Effective Date”), is entered into by and between Gossamer Bio, Inc., a Delaware corporation (the “Company”), and Wilmington Trust, National Association, as trustee under the Indenture (the “Trustee”). Capitalized terms used herein and not otherwise defined
June 5, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2026 GOSSAMER BIO, INC. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2026 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission File Nu
June 5, 2026	EX-10.6	Exhibit 10.6 THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY OTHER APPLICABLE SECURITIES LAWS AND HAVE BEEN ISSUED IN RELIANCE UPON AN EXEMPTION FROM TH goss-20260604xexx106form Exhibit 10.6 THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY OTHER APPLICABLE SECURITIES LAWS AND HAVE BEEN ISSUED IN RELIANCE UPON AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND SUCH OTHER SECURITIES LAWS. NEITHER THIS SECURITY NOR ANY INTEREST OR P
June 5, 2026	EX-10.4	Exhibit 10.4 THIS IS A GLOBAL CERTIFICATE WITHIN THE MEANING OF THE WARRANT AGREEMENT HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF THE DEPOSITARY OR A NOMINEE OF THE DEPOSITARY, WHICH MAY BE TREATED BY THE COMPANY, THE WARRANT AGENT AND A goss-20260604xexx104form Exhibit 10.4 THIS IS A GLOBAL CERTIFICATE WITHIN THE MEANING OF THE WARRANT AGREEMENT HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF THE DEPOSITARY OR A NOMINEE OF THE DEPOSITARY, WHICH MAY BE TREATED BY THE COMPANY, THE WARRANT AGENT AND ANY AGENT THEREOF AS THE OWNER AND HOLDER OF THE WARRANT(S) REPRESENTED BY THIS GLOBAL CERTIFICATE FOR ALL PURPOSES. UNLESS TH
June 5, 2026	EX-10.3	Exhibit 10.3 Gossamer Bio, Inc. and Computershare Inc. and Computershare Trust Company, N.A., as Warrant Agent WARRANT AGREEMENT Dated as of June 4, 2026 - i - Table of Contents Page Section 1. Definitions............................................. goss-20260604xexx103warr Exhibit 10.3 Gossamer Bio, Inc. and Computershare Inc. and Computershare Trust Company, N.A., as Warrant Agent WARRANT AGREEMENT Dated as of June 4, 2026 - i - Table of Contents Page Section 1. Definitions...................................................................................................................1 Section 2. Rules of Construction ....................
June 5, 2026	EX-10.7	Exhibit 10.7 VOTING AND SUPPORT AGREEMENT This VOTING AND SUPPORT AGREEMENT (this “Agreement”), dated as of May 18, 2026, is entered into by and between Gossamer Bio, Inc., a Delaware corporation (the “Company”), and the undersigned (the “Noteholder” goss-20260604xexx107form Exhibit 10.7 VOTING AND SUPPORT AGREEMENT This VOTING AND SUPPORT AGREEMENT (this “Agreement”), dated as of May 18, 2026, is entered into by and between Gossamer Bio, Inc., a Delaware corporation (the “Company”), and the undersigned (the “Noteholder”). The Noteholder is a beneficial owner or investment advisor, sub-advisor or manager of funds and/or accounts that are holde
June 5, 2026	EX-10.2	Exhibit 10.2 [FORM OF] GLOBAL INTERCOMPANY NOTE Dated: [___], [___] FOR VALUE RECEIVED, each of the undersigned, to the extent a borrower (each, in such capacity, a “Payor”) from time to time from any Person from time to time signatory hereto (each, goss-20260604xexx102form Exhibit 10.2 [FORM OF] GLOBAL INTERCOMPANY NOTE Dated: [], [] FOR VALUE RECEIVED, each of the undersigned, to the extent a borrower (each, in such capacity, a “Payor”) from time to time from any Person from time to time signatory hereto (each, in such capacity, a “Payee”), hereby promises to pay on demand to such Person, in lawful money as may be agreed upon from time to t
June 5, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2026 GOSSAMER BIO, INC. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2026 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission File Nu
June 2, 2026	EX-99.1	Gossamer Bio, Inc. Announces Extension of Early Tender Date for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes Exhibit 99.1 Gossamer Bio, Inc. Announces Extension of Early Tender Date for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes San Diego, California. (June 2, 2026) – Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company” or “Gossamer”), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hyp
June 2, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2026 GOSSAMER BIO, INC. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2026 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission File Nu
May 18, 2026	EX-10.2	VOTING AND SUPPORT AGREEMENT Exhibit 10.2 VOTING AND SUPPORT AGREEMENT This VOTING AND SUPPORT AGREEMENT (this “Agreement”), dated as of May 18, 2026, is entered into by and between Gossamer Bio, Inc., a Delaware corporation (the “Company”), and the undersigned (the “Noteholder”). The Noteholder is a beneficial owner or investment advisor, sub-advisor or manager of funds and/or accounts that are holders or beneficial holders
May 18, 2026	EX-10.1	TRANSACTION SUPPORT AGREEMENT Exhibit 10.1 TRANSACTION SUPPORT AGREEMENT This TRANSACTION SUPPORT AGREEMENT (together with all exhibits and attachments hereto, as amended, supplemented, or otherwise modified from time to time in accordance with the terms hereof, this “Agreement”), dated as of May 18, 2026, is entered into by and among: a)Gossamer Bio, Inc., a Delaware corporation (the “Company”) and its undersigned subsidiarie
May 18, 2026	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2026 GOSSAMER BIO, INC. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2026 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission File Nu
May 18, 2026	EX-99.1	Gossamer Bio Announces First Quarter 2026 Financial Results and Provides Business Update - FDA Confirms In-Person Pre-NDA Type B Meeting in Mid-June - - Positive PROSERA CT FRI Results Demonstrated Multiple Statistically Significant Treatment Effects Exhibit 99.1 Gossamer Bio Announces First Quarter 2026 Financial Results and Provides Business Update - FDA Confirms In-Person Pre-NDA Type B Meeting in Mid-June - - Positive PROSERA CT FRI Results Demonstrated Multiple Statistically Significant Treatment Effects, Including Novel Signals Correlated with Clinical Outcomes - - Gossamer Announces Commencement of Exchange Offer and Consent Solicitatio
May 18, 2026	EX-99.2	Gossamer Bio, Inc. Launches Exchange Offer and Consent Solicitation Intended to Eliminate Over $120 Million of Debt with Existing Noteholder Support Exhibit 99.2 Gossamer Bio, Inc. Launches Exchange Offer and Consent Solicitation Intended to Eliminate Over $120 Million of Debt with Existing Noteholder Support San Diego, California (May 18, 2026) – Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company”), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PA
May 18, 2026	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin
May 18, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2026 GOSSAMER BIO, INC. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2026 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission File Nu
May 15, 2026	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission File Number: 001-38796 G
April 24, 2026	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin
April 24, 2026	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin
April 24, 2026	ARS	ARS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K  ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38796 GOSSAMER BIO, INC. (Exact name of Registrant as specified in
April 9, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2026 GOSSAMER BIO, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2026 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission File N
March 17, 2026	EX-21.1	List of Subsidiaries of Gossamer Bio, Inc. Exhibit 21.1 List of Subsidiaries of Gossamer Bio, Inc. Name Jurisdiction of Incorporation or Organization Gossamer Bio 002, Inc. Delaware Gossamer Bio Services, Inc. Delaware Gossamer Bio Holdings, Ltd. Ireland Gossamer Bio 002, Ltd. Ireland
March 17, 2026	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38796 GOSSAMER BIO, INC. (Exact name of Registrant as specified i
March 17, 2026	EX-FILING FEES	Calculation of Filing Fee Tables Form S-3 (Form Type) Gossamer Bio, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Gossamer Bio, Inc.
March 17, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2026 GOSSAMER BIO, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2026 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission File
March 17, 2026	POS AM	As filed with the Securities and Exchange Commission on March 17, 2026 Table of Contents As filed with the Securities and Exchange Commission on March 17, 2026 Registration No.
March 17, 2026	POSASR	As filed with the Securities and Exchange Commission on March 17, 2026 Table of Contents As filed with the Securities and Exchange Commission on March 17, 2026 Registration No.
March 17, 2026	EX-99.1	Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update - Following PROSERA Phase 3 topline results, the Company is focused on evaluating the totality of the dataset, engaging with the FDA, and assessi Exhibit 99.1 Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update - Following PROSERA Phase 3 topline results, the Company is focused on evaluating the totality of the dataset, engaging with the FDA, and assessing strategic options and capital allocation - - Enrollment in the Phase 3 SERANATA Study in PH-ILD has been paused while the Company eval
February 23, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2026 GOSSAMER BIO, I UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2026 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission Fi
February 23, 2026	EX-99.1	Phase 3 PROSERA Topline Results February 2026 Forward Looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding ou proseratlrwebcastslides- Phase 3 PROSERA Topline Results February 2026 Forward Looking Statements This presentation contains forward-looking statements.
January 28, 2026	S-3ASR	As filed with the Securities and Exchange Commission on January 28, 2026 Table of Contents As filed with the Securities and Exchange Commission on January 28, 2026 Registration No.
January 28, 2026	EX-4.4	GOSSAMER BIO, INC. Dated as of ___________, 20___ TABLE OF CONTENTS Exhibit 4.4 GOSSAMER BIO, INC. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions. 1 Section 1.2. Other Definitions. 4 Section 1.3. Incorporation by Reference of Trust Indenture Act. 4 Section 1.4. Rules of Construction. 4 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series. 5 Section 2.2. Establish
January 28, 2026	EX-FILING FEES	Calculation of Filing Fee Tables Form S-3 (Form Type) Gossamer Bio, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Gossamer Bio, Inc.
November 5, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission File Number: 001-387
November 5, 2025	EX-10.1	PERFORMANCE STOCK UNIT GRANT NOTICE Exhibit 10.1 PERFORMANCE STOCK UNIT GRANT NOTICE Capitalized terms not specifically defined in this Performance Stock Unit Grant Notice (the “Grant Notice”) have the meanings given to them in the 2019 Incentive Award Plan (as amended from time to time, the “Plan”) of Gossamer Bio, Inc. (the “Company”). The Company hereby grants to the participant listed below (“Participant”) the Performance Stock
November 5, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2025 GOSSAMER BIO, IN UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2025 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission Fil
November 5, 2025	EX-99.1	Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update - Topline Results from PROSERA Phase 3 Expected in February 2026 - - First Site Activated for Registrational Phase 3 SERANATA Study in PH-ILD - - Cash, cash equi Exhibit 99.1 Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update - Topline Results from PROSERA Phase 3 Expected in February 2026 - - First Site Activated for Registrational Phase 3 SERANATA Study in PH-ILD - - Cash, cash equivalents and marketable securities totaled $180 million as of September 30 - SAN DIEGO—(BUSINESS WIRE)— November 5, 2025 — Gossamer Bio, I
September 25, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 24, 2025 GOSSAMER BIO, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 24, 2025 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission F
August 5, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 GOSSAMER BIO, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission File
August 5, 2025	10-Q	- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
August 5, 2025	EX-99.1	Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update - Topline Results from PROSERA Phase 3 Expected in February 2026 - - First Site Activations for Planned Registrational Phase 3 SERANATA Study in PH-ILD Expected Exhibit 99.1 Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update - Topline Results from PROSERA Phase 3 Expected in February 2026 - - First Site Activations for Planned Registrational Phase 3 SERANATA Study in PH-ILD Expected in the Fourth Quarter of 2025 - - Cash, cash equivalents and marketable securities totaled $213 million as of June 30, 2025 - SAN DIEGO—
June 25, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2025 GOSSAMER BIO, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2025 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission File N
June 16, 2025	EX-99.1	Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH - Enrollment Completed in Ongoing Registrational PROSERA Phase 3 Study in PAH - - Topline Results Announcement from PROSERA Phase 3 Expec Exhibit 99.1 Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH - Enrollment Completed in Ongoing Registrational PROSERA Phase 3 Study in PAH - - Topline Results Announcement from PROSERA Phase 3 Expected in February 2026 - - Blinded Preliminary Baseline Characteristics Align with Intended Study Population - SAN DIEGO—(BUSINESS WIRE)— J
June 16, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2025 GOSSAMER BIO, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2025 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission File N
May 15, 2025	10-Q	- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
May 15, 2025	EX-99.1	Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study - Enrollment Completion for Ongoing Registrational PROSERA Phase 3 Study in PAH Expected in Exhibit 99.1 Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study - Enrollment Completion for Ongoing Registrational PROSERA Phase 3 Study in PAH Expected in Early June; New Patient Screening Closed - - Topline Results Announcement from PROSERA Phase 3 Expected in February 2026 - - To Date, Bli
May 15, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission File Nu
April 29, 2025	ARS	ARS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K  ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38796 GOSSAMER BIO, INC. (Exact name of Registrant as specified i
April 29, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin
April 29, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin
March 13, 2025	S-8	As filed with the Securities and Exchange Commission on March 13, 2025 Table of Contents As filed with the Securities and Exchange Commission on March 13, 2025 Registration No.
March 13, 2025	EX-21.1	List of Subsidiaries of the Registrant. Exhibit 21.1 List of Subsidiaries of Gossamer Bio, Inc. Name Jurisdiction of Incorporation or Organization GB002, LTD. Ireland Gossamer Bio Services, Inc. Delaware
March 13, 2025	EX-99.1	Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update - PROSERA Phase 3 in PAH on Track for Topline Data Readout in Fourth Quarter of 2025 - - Registrational Phase 3 in PH-ILD Expected to Commence in Exhibit 99.1 Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update - PROSERA Phase 3 in PAH on Track for Topline Data Readout in Fourth Quarter of 2025 - - Registrational Phase 3 in PH-ILD Expected to Commence in Second Half of 2025 - - Seralutinib Receives Orphan Drug Designation for PAH in Japan - - Cash, cash equivalents and marketable securitie
March 13, 2025	EX-19.1	Gossamer Bio, Inc. Insider Trading Compliance Policy and Procedures Exhibit 19.1 Gossamer Bio, Inc. Insider Trading Compliance Policy and Procedures Federal and state laws prohibit trading in the securities of a company while in possession of material nonpublic information and in breach of a duty of trust or confidence. These laws also prohibit anyone who is aware of material nonpublic information from providing this information to others who may trade. Violating
March 13, 2025	EX-10.7	Gossamer Bio, Inc. Non-Employee Director Compensation Program. Exhibit 10.7 GOSSAMER BIO, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM Non-employee members of the board of directors (the “Board”) of Gossamer Bio, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). This Program has been adopted under the Company’s 2019 Incentive Award Plan (the “Equity Plan”) and s
March 13, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Gossamer Bio, Inc.
March 13, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2025 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission File
March 13, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38796 GOSSAMER BIO, INC. (Exact name of Registrant as specified i
February 19, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2025 GOSSAMER BIO, I UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2025 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission Fi
November 12, 2024	SC 13G/A	GOSS / Gossamer Bio, Inc. / FMR LLC Passive Investment SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.1 GOSSAMER BIO INC COMMON STOCK Cusip #38341P102 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #38341P102 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 7,920,439 Item 6: 0 Item 7: 7,935,735 Item 8: 0 Item 9: 7,
November 12, 2024	SC 13G/A	GOSS / Gossamer Bio, Inc. / Invus Global Management, LLC - SC 13G/A Passive Investment SC 13G/A 1 d910514dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 2) Gossamer Bio, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 38341P102 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check
November 12, 2024	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 d910514dex991.htm EX-99.1 EXHIBIT 1 JOINT FILING AGREEMENT The undersigned agree that the statement on Schedule 13G with respect to the securities of Gossamer Bio, Inc. is, and any amendments thereto signed by each or any of the undersigned shall be, filed on behalf of each of such person pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act
November 7, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission Fil
November 7, 2024	10-Q	- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
November 7, 2024	EX-99.1	Gossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business Update - $327 Million in Cash, Cash Equivalents & Marketable Securities, as of September 30, 2024 - Exhibit 99.1 Gossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business Update - $327 Million in Cash, Cash Equivalents & Marketable Securities, as of September 30, 2024 - SAN DIEGO—(BUSINESS WIRE)— November 7, 2024 — Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment
September 13, 2024	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2024 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission F
August 12, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2024 GOSSAMER BIO, INC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2024 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission File
August 12, 2024	10-Q	- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
August 12, 2024	EX-99.1	Gossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business Update - $354 Million in Cash, Cash Equivalents & Marketable Securities, as of June 30, 2024 - Exhibit 99.1 Gossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business Update - $354 Million in Cash, Cash Equivalents & Marketable Securities, as of June 30, 2024 - SAN DIEGO—(BUSINESS WIRE)— August 12, 2024 — Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of p
August 12, 2024	EX-10.1	Collaboration and License Agreement dated May 3, 2024 by and among GB002, Inc., Gossamer Bio 002 Ltd. and Gossamer Bio, Inc. on the one hand and CHIESI Farmaceutici S.p.A and CHIESI USA, Inc. on the other hand. Exhibit 10.1 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. COLLABORATION AND LICENSE AGREEMENT by and between GB002, INC., GOSSAMER BIO 002 LTD. and GOSSAMER BIO, INC. and CHIESI FARMACEUTICI S.P.A and CHIESI
August 2, 2024	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 d791379dex991.htm EX-99.1 EXHIBIT 1 JOINT FILING AGREEMENT The undersigned agree that the statement on Schedule 13G with respect to the securities of Gossamer Bio, Inc. is, and any amendments thereto signed by each or any of the undersigned shall be, filed on behalf of each of such person pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act
August 2, 2024	SC 13G/A	GOSS / Gossamer Bio, Inc. / Invus Global Management, LLC - SC 13G/A Passive Investment SC 13G/A 1 d791379dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 1) Gossamer Bio, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 38341P102 (CUSIP Number) July 25, 2024 (Date of Event Which Requires Filing of this Statement) Check the a
July 18, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2024 GOSSAMER BIO, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2024 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission File N
June 10, 2024	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2024 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission File Nu
May 24, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2024 GOSSAMER BIO, INC. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2024 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission File Nu
May 7, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission File Num
May 7, 2024	10-Q	- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
May 7, 2024	EX-99.1	Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update - Transformative Development and Co-Commercialization Collaboration with Chiesi - - Ongoing PROSERA Phase 3 Study in PAH Expected to Readout in Q4 2025 - - Regis Exhibit 99.1 Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update - Transformative Development and Co-Commercialization Collaboration with Chiesi - - Ongoing PROSERA Phase 3 Study in PAH Expected to Readout in Q4 2025 - - Registrational Phase 3 in PH-ILD Expected to Commence in Mid-2025 - - TORREY Phase 2 PAH Results Published in Lancet Respiratory Medicine - -
May 6, 2024	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2024 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission File Num
May 6, 2024	EX-99.1	Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications - Gossamer to receive $160 million development reimbursement payment and eligible to receive up to Exhibit 99.1 Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications - Gossamer to receive $160 million development reimbursement payment and eligible to receive up to $146 million in regulatory and $180 million in sales milestones - - Gossamer leading US commercialization activities in PAH and PH-ILD; 5
April 26, 2024	ARS	ARS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38796 GOSSAMER BIO, INC. (Exact name of Registrant as specified i
April 24, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin
April 24, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin
March 12, 2024	EX-99.1	Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors SAN DIEGO — (BUSINESS WIRE) — March 12, 2024 — Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with inter
March 12, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2024 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission File
March 5, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Gossamer Bio, Inc.
March 5, 2024	S-8	As filed with the Securities and Exchange Commission on March 5, 2024 Table of Contents As filed with the Securities and Exchange Commission on March 5, 2024 Registration No.
March 5, 2024	EX-21.1	List of Subsidiaries of the Registrant. Exhibit 21.1 List of Subsidiaries of Gossamer Bio, Inc. Name Jurisdiction of Incorporation or Organization GB002, Inc. Delaware Gossamer Bio Services, Inc. Delaware
March 5, 2024	EX-97	Policy for Recovery of Erroneously Awarded Compensation Exhibit 97 GOSSAMER BIO, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Gossamer Bio, Inc. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of November 30, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11. 1.Persons Subject to Policy This P
March 5, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38796 GOSSAMER BIO, INC. (Exact name of Registrant as specified i
March 5, 2024	EX-99.1	Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update - First PAH Patient Dosed in Ongoing Registrational Phase 3 PROSERA Study - - Inclusion of Japan in Phase 3 PROSERA Study Following CTN Acceptance Exhibit 99.1 Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update - First PAH Patient Dosed in Ongoing Registrational Phase 3 PROSERA Study - - Inclusion of Japan in Phase 3 PROSERA Study Following CTN Acceptance by PMDA - - Cash, cash equivalents and marketable securities totaled $296 million at year-end 2023 - SAN DIEGO — (BUSINESS WIRE) — March
March 5, 2024	EX-10.15	Employment Letter, dated November 25, 2023, by and between Robert Smith and the Registrant. Exhibit 10.15 Gossamer Bio Services, Inc. 3013 Science Park Road San Diego, CA 92112 November 25, 2023 Robert Smith 30211 Fairway Ash Fair Oaks Ranch, Texas 78015 Dear Bob: This letter agreement (this “Agreement”) confirms the terms of your employment with Gossamer Bio Services, Inc. (the “Company”), a wholly-owned subsidiary of Gossamer Bio, Inc. (the “Parent”). This Agreement is effective as of
March 5, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2024 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission File N
March 5, 2024	EX-10.7	Gossamer Bio, Inc. Non-Employee Director Compensation Program. Exhibit 10.7 GOSSAMER BIO, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM Non-employee members of the board of directors (the “Board”) of Gossamer Bio, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). This Program has been adopted under the Company’s 2019 Incentive Award Plan (the “Equity Plan”) and s
March 4, 2024	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2024 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission File N
February 14, 2024	SC 13G/A	GOSS / Gossamer Bio, Inc. / HILLHOUSE CAPITAL MANAGEMENT, LTD. - GOSSAMER BIO, INC. Passive Investment SC 13G/A 1 p24-0572sc13ga.htm GOSSAMER BIO, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Gossamer Bio, Inc. (Name of Issuer) Common Stock, par value of $0.0001 per share (Title of Class of Securities) 38341P102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check
February 13, 2024	SC 13G/A	GOSS / Gossamer Bio, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01037-gossamerbioinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Gossamer Bio Inc Title of Class of Securities: Common Stock CUSIP Number: 38341P102 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate th
February 9, 2024	SC 13G	GOSS / Gossamer Bio, Inc. / FMR LLC Passive Investment SC 13G 1 filing.txt SCHEDULE 13G Amendment No.0 GOSSAMER BIO INC COMMON STOCK Cusip #38341P102 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #38341P102 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 12,185,367 Item 6: 0 Item 7: 12,263,918 Item 8: 0 Item 9: 12
February 9, 2024	SC 13G/A	GOSS / Gossamer Bio, Inc. / ARCH Venture Fund IX, L.P. - ARCH VENTURE FUND IX, L.P. - GOSSAMER BIO -- SCH 13G/A(#1-EXIT) Passive Investment SC 13G/A 1 arch-sch13g18793.htm ARCH VENTURE FUND IX, L.P. - GOSSAMER BIO - SCH 13G/A(#1-EXIT) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 – Exit Filing)* Gossamer Bio, Inc. (Name of Issuer) Common Stock par value $0.0001 per share (Title of Class of Securities) 38341P102 (CUSIP Number) July 24, 202
January 11, 2024	SC 13G/A	GOSS / Gossamer Bio, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) GOSSAMER BIO, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 38341P102 (CUSIP Number) DECEMBER 31, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule
January 11, 2024	SC 13G	GOSS / Gossamer Bio, Inc. / Artal International S.C.A. - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No.) Gossamer Bio, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 38341P102 (CUSIP Number) December 14, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th
January 11, 2024	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 d723472dex991.htm EX-99.1 EXHIBIT 1 JOINT FILING AGREEMENT The undersigned agree that the statement on Schedule 13G with respect to the Common Stock, $0.0001 par value per share, of Gossamer Bio, Inc. is, and any amendments thereto signed by each of the undersigned shall be, filed on behalf of each of them pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Secur
November 29, 2023	EX-99.1	Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors SAN DIEGO — (BUSINESS WIRE) — November 29, 2023 — Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced the appointment of John Quisel, J.D., Ph.D
November 29, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2023 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission Fi
November 27, 2023	EX-10.1	Gossamer Bio, Inc. 2023 Employment Inducement Incentive Award Plan and Form of Stock Option Agreement thereunder. GOSSAMER BIO, INC. 2023 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN ARTICLE I. PURPOSE The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate Eligible Individuals who are expected to make important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in the Plan are defined in Article XI. ARTICLE II.
November 27, 2023	EX-3.1	Amended and Restated Bylaws AMENDED AND RESTATED BYLAWS OF GOSSAMER BIO, INC. (a Delaware corporation) TABLE OF CONTENTS Page Article I CORPORATE OFFICES 1 1.1 REGISTERED OFFICE. 1 1.2 OTHER OFFICES. 1 Article II MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 2.5 ADVANCE NOTICE PROCEDURES FOR NOMINATIONS OF DI
November 27, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2023 GOSSAMER BIO, I UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2023 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission Fi
November 9, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission Fil
November 9, 2023	10-Q	- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
November 9, 2023	EX-99.1	Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business Update - Phase 3 PROSERA Site Activations Proceeding Ahead of Schedule; First Dosing Expected in 4Q23 - - Additional Data from TORREY Open-Label Extension Expected in 4 Exhibit 99.1 Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business Update - Phase 3 PROSERA Site Activations Proceeding Ahead of Schedule; First Dosing Expected in 4Q23 - - Additional Data from TORREY Open-Label Extension Expected in 4Q23 - - $329 Million in Cash, Cash Equivalents & Marketable Securities, as of September 30, 2023 - SAN DIEGO—(BUSINESS WIRE)— November 9,
October 20, 2023	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2023 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission Fil
September 7, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2023 GOSSAMER BIO, I UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2023 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission Fi
August 28, 2023	424B3	162,336,800 Shares of Common Stock Table of Contents As filed Pursuant to Rule 424(b)(3) Registration No. 333-274056 PROSPECTUS 162,336,800 Shares of Common Stock This prospectus relates to the proposed resale or other disposition by the selling securityholders identified in this prospectus of up to (i) 129,869,440 shares of our common stock, par value $0.0001 per share and (ii) up to 32,467,360 shares of common stock issuable upon
August 24, 2023	CORRESP	Gossamer Bio, Inc. 3013 Science Park Road San Diego, CA 92121 Gossamer Bio, Inc. 3013 Science Park Road San Diego, CA 92121 August 24, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Gossamer Bio, Inc. Registration Statement on Form S-3 File No. 333-274056 To the addressees set forth above: Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the S
August 24, 2023	LETTER	LETTER United States securities and exchange commission logo August 24, 2023 Jeff Boerneke General Counsel Gossamer Bio, Inc.
August 21, 2023	DEL AM	GOSSAMER BIO, INC. 3013 SCIENCE PARK ROAD SAN DIEGO, CA 92121 GOSSAMER BIO, INC. 3013 SCIENCE PARK ROAD SAN DIEGO, CA 92121 August 21, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: Delaying Amendment for Gossamer Bio, Inc. Registration Statement on Form S-3 (File No. 333-274056) Ladies and Gentlemen: Reference is made to the Registration Statement on Form S-3 (File
August 18, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Gossamer Bio, Inc.
August 18, 2023	RW	GOSSAMER BIO, INC. 3013 SCIENCE PARK ROAD SAN DIEGO, CA 92121 GOSSAMER BIO, INC. 3013 SCIENCE PARK ROAD SAN DIEGO, CA 92121 August 18, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Gossamer Bio, Inc. – Application for Withdrawal of Registration Statement on Form S-3ASR (File No. 333-274045) To Whom It May Concern: Gossamer Bio, Inc. (the “Company” or “Gossamer”) hereby reque
August 18, 2023	S-3	As filed with the Securities and Exchange Commission on August 18, 2023 Table of Contents As filed with the Securities and Exchange Commission on August 18, 2023 Registration No.
August 17, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Gossamer Bio, Inc.
August 17, 2023	S-3ASR	As filed with the Securities and Exchange Commission on August 17, 2023 Table of Contents As filed with the Securities and Exchange Commission on August 17, 2023 Registration No.
August 8, 2023	EX-99.1	Gossamer Bio Announces Second Quarter 2023 Financial Results and Provides Business Update - Seralutinib Phase 3 PROSERA Study in PAH Patients Expected to Initiate in 3Q23 - - Additional Data from TORREY Open-Label Extension Expected in 4Q23 or 1Q24 - Exhibit 99.1 Gossamer Bio Announces Second Quarter 2023 Financial Results and Provides Business Update - Seralutinib Phase 3 PROSERA Study in PAH Patients Expected to Initiate in 3Q23 - - Additional Data from TORREY Open-Label Extension Expected in 4Q23 or 1Q24 - - $374 Million in Cash, Cash Equivalents & Marketable Securities, as of June 30, 2023, Pro Forma for Gross Proceeds of $212 Million from
August 8, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 GOSSAMER BIO, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission File
August 8, 2023	EX-10.1	Form of Option Repricing and Cancellation Agreement Exhibit 10.1 Stock Option Cancellation Agreement and Amendment to Option Agreement(s) This Stock Option Cancellation Agreement and Amendment to Option Agreement(s) (the “Amendment”) is made and entered into effective as of May 5, 2023 (the “Amendment Date”) by and between Gossamer Bio, Inc. (“Gossamer”) and (“Optionee”). Pursuant to this Amendment, Gossamer and Optionee hereby agree to amend the s
August 8, 2023	EX-3.1	Amended and Restated Certificate of Incorporation, as amended. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF GOSSAMER BIO, INC. (originally incorporated on October 26, 2015 under the name FSG Bio,Inc.) FIRST: The name of the Corporation is Gossamer Bio, Inc. SECOND: The address of the Corporation's registered office in the State of Delaware is 251 Little Falls Drive, City of Wilmington, County of New Castle, State of Delaware 19808. The nam
August 8, 2023	10-Q	- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
July 28, 2023	SC 13D	GOSS / Gossamer Bio Inc / Growth Equity Opportunities 18 VGE, LLC - GROWTH EQUITY OPPORTUNITIES 18 VGE, LLC / GOSSAMER BIO, INC. -- SCHEDULE 13D Activist Investment Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Gossamer Bio, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 38341P102 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842-4000 (
July 20, 2023	EX-99.1	Interim TORREY OLE Update and PROSERA Phase 3 Design July 2023 Forward Looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statem goss-oleupdate8xkx202307 Interim TORREY OLE Update and PROSERA Phase 3 Design July 2023 Forward Looking Statements This presentation contains forward-looking statements.
July 20, 2023	EX-4.1	Form of Warrant Exhibit 4.1 THE OFFER AND SALE OF THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THE HOLDER MAY NOT OFFER, SELL, TRANSFER, ASSIGN, PLEDGE, HYPOTHECATE, OR OTHERWISE DISPOSE OF OR ENCUMBER SUCH SECURITIES EXCEPT (I) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT AND THE RULES AND REGULATIONS P
July 20, 2023	EX-99.1	Gossamer Bio Announces $212 Million Private Placement Financing - In Conjunction with Offering, Interim TORREY OLE Data and PROSERA Phase 3 Design Disclosed via 8-K; Conference Call to Discuss Data and Phase 3 Design with Leading PAH KOLs to be Held Exhibit 99.1 Gossamer Bio Announces $212 Million Private Placement Financing - In Conjunction with Offering, Interim TORREY OLE Data and PROSERA Phase 3 Design Disclosed via 8-K; Conference Call to Discuss Data and Phase 3 Design with Leading PAH KOLs to be Held on July 25th - SAN DIEGO – July 20, 2023 – Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the d
July 20, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2023 GOSSAMER BIO, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2023 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission File N
July 20, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2023 GOSSAMER BIO, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2023 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission File N
July 20, 2023	EX-10.1	Form of Securities Purchase Agreement. Exhibit 10.1 GOSSAMER BIO, INC. SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (the “Agreement”) is made as of July 19, 2023 (the “Effective Date”), by and among Gossamer Bio, Inc., a Delaware corporation (the “Company”), and the purchasers whose names and addresses are set forth on the signature pages hereof (each, a “Purchaser” and, collectively, the “Purchasers”). Whereas, the
June 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2023 GOSSAMER BIO, INC. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2023 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission File Nu
June 9, 2023	EX-3.1	Certificate of Amendment to Amended and Restated Certificate of Incorporation, dated June 8, 2023 goss-charteramendmentjun CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF GOSSAMER BIO, INC.
May 10, 2023	SC 13G/A	GOSS / Gossamer Bio Inc / STATE STREET CORP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 EXIT FILING GOSSAMER BIO INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 38341P102 (CUSIP NUMBER) 04/30/2023 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE IS FILED: (
May 9, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission File Number: 001-38796 G
May 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 GOSSAMER BIO, INC. (E UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission File Num
May 9, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin
May 9, 2023	EX-99.1	Gossamer Bio Announces First Quarter 2023 Financial Results and Provides Business Update - Feedback on Planned Registrational Program for Seralutinib Received from FDA and EMA following Successful Phase 2 TORREY Study - - Registrational Phase 3 Clini Exhibit 99.1 Gossamer Bio Announces First Quarter 2023 Financial Results and Provides Business Update - Feedback on Planned Registrational Program for Seralutinib Received from FDA and EMA following Successful Phase 2 TORREY Study - - Registrational Phase 3 Clinical Trial in PAH Patients Expected to Initiate in 3Q23 - - Initial TORREY Study Open-Label Extension Data Expected Mid 2023 - - Operation
May 5, 2023	SC 13G/A	GOSS / Gossamer Bio Inc / BlackRock Inc. Passive Investment us38341p1021050423.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 3) GOSSAMER BIO, INC. - (Name of Issuer) Common Stock - (Title of Class of Securities) 38341P102 - (CUSIP Number) April 30, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh
April 28, 2023	ARS	ARS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38796 GOSSAMER BIO, INC. (Exact name of Registrant as specified i
April 28, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin
April 28, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin
April 17, 2023	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin
April 3, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2023 GOSSAMER BIO, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2023 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission File N
March 17, 2023	EX-10.24	Fourth Amendment to Credit, Guarantee and Security Agreement, dated February 14, 2023, by and among the Registrant, GB001, Inc., GB002, Inc. and GB004, Inc., as co-borrowers, the other guarantors from time to time party thereto and MidCap Financial Trust, as Agent and as a Lender and the additional lenders from time to time party thereto. Exhibit 10.24 Execution Version CONSENT AND RELEASE This CONSENT AND RELEASE (this “Agreement”) is made as of this 14 day of February, 2023 (“Effective Date”), by and among GB001, INC., a Delaware corporation (“GB001”), GOSSAMER BIO, INC., Delaware corporation (“Parent”), GB002, INC., a Delaware corporation (“GB002”), GB004, INC., a Delaware corporation (“GB004” and GB004 together with Parent, GB0
March 17, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2023 GOSSAMER BIO, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2023 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission File
March 17, 2023	EX-21.1	List of Subsidiaries of the Registrant. Exhibit 21.1 List of Subsidiaries of Gossamer Bio, Inc. Name Jurisdiction of Incorporation or Organization GB002, Inc. Delaware GB005, Inc. Delaware Gossamer Bio Services, Inc. Delaware
March 17, 2023	EX-10.7	Gossamer Bio, Inc. Non-Employee Director Compensation Program. Exhibit 10.7 GOSSAMER BIO, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM Non-employee members of the board of directors (the “Board”) of Gossamer Bio, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). This Program has been adopted under the Company’s 2019 Incentive Award Plan (the “Equity Plan”) and s
March 17, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38796 GOSSAMER BIO, INC. (Exact name of Registrant as specified i
March 17, 2023	EX-10.23	and Security Agreement, dated December 7, 2022, by and among the Registrant, GB001, Inc., GB002, Inc. and GB004, Inc., as co-borrowers, the other guarantors from time to time party thereto and MidCap Financial Trust, as Agent and as a Lender and the additional lenders from time to time party thereto. Exhibit 10.23 Execution Version THIRD AMENDMENT TO CREDIT, GUARANTY AND SECURITY AGREEMENT This THIRD AMENDMENT TO CREDIT, GUARANTY AND SECURITY AGREEMENT (this “Agreement”) is made as of this 7th day of December, 2022 (“Effective Date”), by and among GB001, INC., a Delaware corporation (“GB001”), GOSSAMER BIO, INC., Delaware corporation (“Parent”), GB002, INC., a Delaware corporation (“GB002”), G
March 17, 2023	EX-99.1	Gossamer Bio Announces Fourth Quarter and Full-Year 2022 Financial Results and Provides Business Update - FDA Feedback on Seralutinib Phase 3 Clinical Trial Received; Expected to Commence in the Second Half of 2023 - - Topline Data from TORREY Study Exhibit 99.1 Gossamer Bio Announces Fourth Quarter and Full-Year 2022 Financial Results and Provides Business Update - FDA Feedback on Seralutinib Phase 3 Clinical Trial Received; Expected to Commence in the Second Half of 2023 - - Topline Data from TORREY Study Open-Label Extension Expected in Mid-2023 - - Enrollment in GB5121 Phase 1b/2 Clinical Trial in PCNSL Paused - - Cash, cash equivalents a
February 14, 2023	SC 13G/A	GOSS / Gossamer Bio Inc / HILLHOUSE CAPITAL ADVISORS, LTD. - GOSSAMER BIO, INC. Passive Investment SC 13G/A 1 p23-0182sc13ga.htm GOSSAMER BIO, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Gossamer Bio, Inc. (Name of Issuer) Common Stock, par value of $0.0001 per share (Title of Class of Securities) 38341P102 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statement) Check
February 9, 2023	SC 13G/A	GOSS / Gossamer Bio Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment
February 1, 2023	SC 13G/A	GOSS / Gossamer Bio Inc / BlackRock Inc. Passive Investment SC 13G/A 1 us38341p1021020123.txt us38341p1021020123.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) GOSSAMER BIO, INC. - (Name of Issuer) Common Stock - (Title of Class of Securities) 38341P102 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box
January 10, 2023	SC 13G	GOSS / Gossamer Bio Inc / STATE STREET CORP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 INITIAL FILING GOSSAMER BIO INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 38341P102 (CUSIP NUMBER) 12/31/2022 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE IS FILED
January 4, 2023	SC 13G	GOSS / Gossamer Bio Inc / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 GOSSAMER BIO, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 38341P102 (CUSIP Number) DECEMBER 29, 2022 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which
December 20, 2022	SC 13G	GOSS / Gossamer Bio Inc / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 GOSSAMER BIO, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 38341P102 (CUSIP Number) DECEMBER 12, 2022 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which
December 6, 2022	EX-99.1	Phase 2 TORREY Study Topline Results 1 December 6, 2022 Exhibit 99.1 Forward Looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including gb002-2101torreytopliner Phase 2 TORREY Study Topline Results 1 December 6, 2022 Exhibit 99.
December 6, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2022 GOSSAMER BIO, IN UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2022 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission Fil
November 3, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission Fil
November 3, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission File Number: 001-387
November 3, 2022	EX-99.1	Gossamer Bio Announces Third Quarter 2022 Financial Results and Provides Business Update - Seralutinib Phase 2 TORREY Study on track for topline readout in second half of November or first half of December - - $304 million in cash, cash equivalents & Exhibit 99.1 Gossamer Bio Announces Third Quarter 2022 Financial Results and Provides Business Update - Seralutinib Phase 2 TORREY Study on track for topline readout in second half of November or first half of December - - $304 million in cash, cash equivalents & marketable securities, as of September 30, 2022 SAN DIEGO?(BUSINESS WIRE)? November 3, 2022 ? Gossamer Bio, Inc. (Nasdaq: GOSS), a clini
August 9, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Gossamer Bio, Inc.
August 9, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission File Number: 001-38796 GO
August 9, 2022	EX-10.1	Second Amendment to Sublease Agreement, dated June 1, 2022, by and between the Medicines Company and the Registrant. EXHIBIT 10.1 SECOND AMENDMENT TO SUBLEASE THIS SECOND AMENDMENT TO SUBLEASE ("Amendment 2") is made and entered into as of the 1st day of June, 2022, by and between THE MEDICINES COMPANY, a Delaware corporation ("Sublessor"), and GOSSAMER BIO, INC., a Delaware corporation ("Sublessee"). R E C I T A L S : A.Sublessor and Sublessee entered into that certain Sublease dated as of December 29, 2017 (th
August 9, 2022	EX-99.1	Gossamer Bio Announces Second Quarter 2022 Financial Results and Provides Business Update - Seralutinib Phase 2 TORREY Study on track for topline readout in second half of November or first half of December - - CNS-penetrant GB5121 doses first patien Exhibit 99.1 Gossamer Bio Announces Second Quarter 2022 Financial Results and Provides Business Update - Seralutinib Phase 2 TORREY Study on track for topline readout in second half of November or first half of December - - CNS-penetrant GB5121 doses first patient in Phase 1b/2 STAR CNS Study in PCNSL and other rare CNS malignancies - - $342 million in cash, cash equivalents & marketable securitie
August 9, 2022	S-3ASR	As filed with the Securities and Exchange Commission on August 9, 2022 Table of Contents As filed with the Securities and Exchange Commission on August 9, 2022 Registration No.
August 9, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2022 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission File
July 13, 2022	EX-99.1	Gossamer Bio Announces $120 million Private Placement Financing Exhibit 99.1 Gossamer Bio Announces $120 million Private Placement Financing SAN DIEGO ? July 13, 2022 ? Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, announced today it has agreed to sell approximately 16.6 million shares of
July 13, 2022	EX-10.1	Stock Purchase Agreement, dated July 12, 2022, by and among the Registrant and the Purchasers named therein. Exhibit 10.1 GOSSAMER BIO, INC. STOCK PURCHASE AGREEMENT This Stock Purchase Agreement (the ?Agreement?) is made as of July 12, 2022 (the ?Effective Date?), by and among Gossamer Bio, Inc., a Delaware corporation (the ?Company?), and the purchasers whose names and addresses are set forth on the signature pages hereof (each, a ?Purchaser? and, collectively, the ?Purchasers?). Whereas, in furtheranc
July 13, 2022	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2022 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission File N
June 10, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2022 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission File Nu
May 10, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission File Nu
May 10, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission File Number: 001-38796 G
May 10, 2022	EX-99.1	Gossamer Bio Announces First Quarter 2022 Financial Results and Provides Business Update - Seralutinib (GB002) completed PAH patient enrollment in Phase 2 TORREY Study - - Topline results from Phase 2 TORREY Study expected in the fourth quarter of 20 Exhibit 99.1 Gossamer Bio Announces First Quarter 2022 Financial Results and Provides Business Update - Seralutinib (GB002) completed PAH patient enrollment in Phase 2 TORREY Study - - Topline results from Phase 2 TORREY Study expected in the fourth quarter of 2022 - - Cash, cash equivalents & marketable securities totaled $272 million as of March 31, 2022 - SAN DIEGO?(BUSINESS WIRE)? May 10, 2022
April 27, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
April 27, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEF 14A 1 goss-2022xdef14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as
April 25, 2022	8-K	Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2022 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission File
March 3, 2022	EX-99.1	Gossamer Bio Announces Fourth Quarter and Full-Year 2021 Financial Results and Provides Business Update - GB004 topline results for the Phase 2 SHIFT-UC study in mild-to-moderate UC expected in the second quarter of 2022 - - Seralutinib (GB002) topli Exhibit 99.1 Gossamer Bio Announces Fourth Quarter and Full-Year 2021 Financial Results and Provides Business Update - GB004 topline results for the Phase 2 SHIFT-UC study in mild-to-moderate UC expected in the second quarter of 2022 - - Seralutinib (GB002) topline results for the Phase 2 TORREY study in PAH expected in the second half of 2022, subject to developments in the ongoing COVID-19 pande
March 3, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Gossamer Bio, Inc.
March 3, 2022	EX-10.7	Gossamer Bio, Inc. Non-Employee Director Compensation Program. Exhibit 10.7 GOSSAMER BIO, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM Non-employee members of the board of directors (the ?Board?) of Gossamer Bio, Inc. (the ?Company?) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this ?Program?). This Program has been adopted under the Company?s 2019 Incentive Award Plan (the ?Equity Plan?) and s
March 3, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2022 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission File N
March 3, 2022	S-8	As filed with the Securities and Exchange Commission on March 3, 2022 Table of Contents As filed with the Securities and Exchange Commission on March 3, 2022 Registration No.
March 3, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Gossamer Bio, Inc.
March 3, 2022	EX-4.4	Form of Indenture GOSSAMER BIO, INC. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions. 1 Section 1.2. Other Definitions. 4 Section 1.3. Incorporation by Reference of Trust Indenture Act. 4 Section 1.4. Rules of Construction. 4 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series. 5 Section 2.2. Establishment of Term
March 3, 2022	S-3ASR	As filed with the Securities and Exchange Commission on March 3, 2022 Table of Contents As filed with the Securities and Exchange Commission on March 3, 2022 Registration No.
March 3, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38796 GOSSAMER BIO, INC. (Exact name of Registrant as specified i
March 3, 2022	EX-21.1	List of Subsidiaries of the Registrant. Exhibit 21.1 List of Subsidiaries of Gossamer Bio, Inc. Name Jurisdiction of Incorporation or Organization GB002, Inc. Delaware GB004, Inc. Delaware Gossamer Bio Services, Inc. Delaware
February 10, 2022	SC 13G/A	GOSS / Gossamer Bio Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Gossamer Bio Inc. Title of Class of Securities: Common Stock CUSIP Number: 38341P102 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ R
February 3, 2022	SC 13G/A	GOSS / Gossamer Bio Inc / BlackRock Inc. Passive Investment us38341p1021020322.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) GOSSAMER BIO, INC. - (Name of Issuer) Common Stock - (Title of Class of Securities) 38341P102 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to
November 8, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPORT PURSUANT Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission File Number: 001-387
November 8, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2021 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission Fil
November 8, 2021	EX-99.1	Gossamer Bio Announces Third Quarter 2021 Financial Results and Provides Corporate Update - Topline Results from Ongoing Phase 2 TORREY Study of Seralutinib in Patients with PAH Now Expected in Second Half of 2022, Due to COVID-19-Related Delays - - Exhibit 99.1 Gossamer Bio Announces Third Quarter 2021 Financial Results and Provides Corporate Update - Topline Results from Ongoing Phase 2 TORREY Study of Seralutinib in Patients with PAH Now Expected in Second Half of 2022, Due to COVID-19-Related Delays - - Phase 2 SHIFT-UC Study of GB004 in Patients with UC has Completed Enrollment with 12-Week Topline Results Expected in the Second Quarter
October 12, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2021 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission Fil
October 12, 2021	EX-99.1	Gossamer Bio Announces Addition of Two CNS-Penetrant BTK Inhibitors to its Product Candidate Pipeline: GB5121 & GB7208 Exhibit 99.1 Gossamer Bio Announces Addition of Two CNS-Penetrant BTK Inhibitors to its Product Candidate Pipeline: GB5121 & GB7208 SAN DIEGO ? (BUSINESS WIRE) ? October 11, 2021 ? Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology,
September 21, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2021 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission F
September 21, 2021	EX-99.1	Gossamer Bio Announces Appointment of Bryan Giraudo as Chief Operating Officer, in addition to Chief Financial Officer Role Exhibit 99.1 Gossamer Bio Announces Appointment of Bryan Giraudo as Chief Operating Officer, in addition to Chief Financial Officer Role SAN DIEGO ? (BUSINESS WIRE) ? September 21, 2021 ? Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and on
August 9, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission File Number: 001-38796 GO
August 9, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2021 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission File
August 9, 2021	EX-10.2	Employment Letter, dated May 1, 2021, by and between Laura Carter and the Registrant. EXHIBIT 10.2 Gossamer Bio Services, Inc. 3013 Science Park Road San Diego, CA 92112 May 1, 2021 Laura Carter c/o Gossamer Bio Services, Inc. 3013 Science Park Road, Suite 200 San Diego, CA 92112 Dear Laura: This amended and restated letter agreement (this ?Agreement?) confirms the terms of your continuing employment with Gossamer Bio Services, Inc. (the ?Company?), a wholly-owned subsidiary of Gos
August 9, 2021	EX-10.3	Employment Letter, dated June 21, 2021, by and between Richard Aranda and the Registrant. EXHIBIT 10.2 Gossamer Bio Services, Inc. 3013 Science Park Road San Diego, CA 92112 June 21, 2021 Richard Aranda c/o Gossamer Bio Services, Inc. 3013 Science Park Road San Diego, CA 92112 Dear Richard: This amended and restated letter agreement (this ?Agreement?) confirms the terms of your continuing employment with Gossamer Bio Services, Inc. (the ?Company?), a wholly-owned subsidiary of Gossamer
August 9, 2021	EX-99.1	Gossamer Bio Announces Second Quarter 2021 Financial Results and Provides Corporate Update - Seralutinib and GB004 continue to enroll ongoing Phase 2 TORREY and SHIFT-UC clinical trials for Pulmonary Arterial Hypertension (PAH) and Ulcerative Colitis Exhibit 99.1 Gossamer Bio Announces Second Quarter 2021 Financial Results and Provides Corporate Update - Seralutinib and GB004 continue to enroll ongoing Phase 2 TORREY and SHIFT-UC clinical trials for Pulmonary Arterial Hypertension (PAH) and Ulcerative Colitis (UC), respectively - - Gossamer Announces Seralutinib Open Label Extension Data in PAH Patients - - Gossamer to Discontinue Clinical Dev
August 9, 2021	EX-10.1	Employment Letter, dated April 16, 2021, by and between Caryn Peterson and the Registrant. EXHIBIT 10.1 Gossamer Bio Services, Inc. 3013 Science Park Road San Diego, CA 92112 April 16, 2021 Caryn Peterson c/o Gossamer Bio Services, Inc. 3013 Science Park Road, Suite 200 San Diego, CA 92112 Dear Caryn: This amended and restated letter agreement (this ?Agreement?) confirms the terms of your continuing employment with Gossamer Bio Services, Inc. (the ?Company?), a wholly-owned subsidiary o
June 14, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2021 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission File Nu
June 14, 2021	EX-99.1	Gossamer Bio Announces Appointment of Sandra Milligan, M.D., J.D., to its Board of Directors Gossamer Bio Announces Appointment of Sandra Milligan, M.D., J.D., to its Board of Directors SAN DIEGO ? (BUSINESS WIRE) ? June 14, 2021 ? Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the appointment of Sandra
May 6, 2021	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission File Number: 001-38796 G
May 6, 2021	EX-10.1	Director Compensation Prog Exhibit 10.1 GOSSAMER BIO, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM Non-employee members of the board of directors (the ?Board?) of Gossamer Bio, Inc. (the ?Company?) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this ?Program?). This Program has been adopted under the Company?s 2019 Incentive Award Plan (the ?Equity Plan?) and s
May 6, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission File Num
May 6, 2021	EX-99.1	Gossamer Bio Announces First Quarter 2021 Financial Results and Provides Corporate Update - Seralutinib and GB004 continue to progress through ongoing Phase 2 TORREY and SHIFT-UC clinical trials for Pulmonary Arterial Hypertension (PAH) and Ulcerativ Exhibit 99.1 Gossamer Bio Announces First Quarter 2021 Financial Results and Provides Corporate Update - Seralutinib and GB004 continue to progress through ongoing Phase 2 TORREY and SHIFT-UC clinical trials for Pulmonary Arterial Hypertension (PAH) and Ulcerative Colitis (UC), respectively - - Cash, cash equivalents and marketable securities totaled $453 million as of March 31, 2021 - SAN DIEGO?(
April 27, 2021	DEF 14A	- DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin
April 27, 2021	DEFA14A	- DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
April 20, 2021	EX-99.1	Gossamer Bio Announces Executive Management Transition and Promotion of Laura Carter, Ph.D., to Chief Scientific Officer Exhibit 99.1 Gossamer Bio Announces Executive Management Transition and Promotion of Laura Carter, Ph.D., to Chief Scientific Officer SAN DIEGO ? (BUSINESS WIRE) ? April 20, 2021 ? Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology,
April 20, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2021 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission File
February 26, 2021	10-K	Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38796 GOSSAMER BIO, INC. (Exact name of Registrant as specified i
February 26, 2021	EX-10.11	Letter Agreement, dated November 16, 2020, by and between Faheem Hasnain and the Registrant. Exhibit 10.11 Gossamer Bio, Inc. Gossamer Bio Services, Inc. November 16, 2020 Faheem Hasnain c/o Gossamer Bio, Inc. 3013 Science Park Road San Diego, CA 92121 Dear Mr. Hasnain: The purpose of this letter agreement (this ?Agreement?) is to memorialize the terms and conditions of your employment as President and Chief Executive Officer of Gossamer Bio, Inc. (?Parent?) and continued service as Chair
February 26, 2021	EX-4.3	Description of Securities Registered under Section 12 of the Exchange Act. Exhibit 4.3 DESCRIPTION OF GOSSAMER BIO, INC. SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Gossamer Bio, Inc. has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): our common stock, par value $0.0001 per share (the ?common stock?). DESCRIPTION OF COMMON STOCK The following description
February 26, 2021	EX-10.10	Transition Agreement, dated November 17, 2020, by and between Sheila Gujrathi, M.D. and the Registrant. Exhibit 10.10 TRANSITION AGREEMENT This Transition Agreement (the ?Agreement?) is entered into by and among Sheila Gujrathi, M.D. (?Executive?), Gossamer Bio Services, Inc. (the ?Gossamer Services?), and Gossamer Bio, Inc. (?Parent,? and together with Gossamer Services, collectively the ?Company?), effective as of the Effective Date (as defined below). Recitals WHEREAS, Executive is a party to tha
February 25, 2021	EX-99.1	Gossamer Bio Announces Fourth Quarter and Full-Year 2020 Financial Results and Provides Business Update - Seralutinib (GB002) and GB004 continue to progress through ongoing Phase 2 TORREY and SHIFT-UC clinical trials for Pulmonary Arterial Hypertensi Exhibit 99.1 Gossamer Bio Announces Fourth Quarter and Full-Year 2020 Financial Results and Provides Business Update - Seralutinib (GB002) and GB004 continue to progress through ongoing Phase 2 TORREY and SHIFT-UC clinical trials for Pulmonary Arterial Hypertension (PAH) and Ulcerative Colitis (UC), respectively - - Topline results for both ongoing Phase 2 trials expected in the first half of 2022
February 25, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2021 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission Fi
February 16, 2021	SC 13G/A	Gossamer Bio, Inc. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Gossamer Bio, Inc. (Name of Issuer) Common Stock, par value of $0.0001 per share (Title of Class of Securities) 38341P102 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuan
February 12, 2021	SC 13G/A	SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 1)* Goss SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2 (Amendment No. 1)* Gossamer Bio, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 38341P102 (CUSIP Number) December 31, 2020 (Date of Event Which Requires F
February 12, 2021	SC 13G	United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to ? 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to ? 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* GOSSAMER BIO, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 38341P102 (CUSIP Nu
February 12, 2021	EX-99.2	POWER OF ATTORNEY EX-99.2 CUSIP No. 38341P102 13G Exhibit 99.2 POWER OF ATTORNEY Know all by these presents, that each of the undersigned hereby constitutes and appoints each other undersigned, such person’s true and lawful attorney-in-fact, to: (1) execute for and on behalf of each of such person Forms 3, 4, and 5 and Schedules 13D or 13G, as appropriate, and any required amendments thereto (collectively, the “Rep
February 12, 2021	EX-99.1	AGREEMENT EX-99.1 CUSIP No. 38341P102 13G Exhibit 99.1 AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of Common Stock of Gossamer Bio, Inc. Dated: February 12, 2021 OMEGA FUND V, L.P. BY:
February 12, 2021	SC 13G	United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to ? 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to ? 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* GOSSAMER BIO, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 38341P102 (CUSIP Nu
February 10, 2021	SC 13G/A	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Gossamer Bio Inc. Title of Class of Securities: Common Stock CUSIP Number: 38341P102 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ R
February 2, 2021	SC 13G	SC 13G us38341p1021020221.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) GOSSAMER BIO, INC. - (Name of Issuer) Common Stock - (Title of Class of Securities) 38341P102 - (CUSIP Number) December 31, 2020 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to
November 17, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2020 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission Fi
November 10, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2020 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission Fi
November 10, 2020	EX-99.1	Gossamer Bio Announces Third Quarter 2020 Financial Results and Provides Corporate Update - GB004: SHIFT-UC Phase 2 trial enrolling patients with active ulcerative colitis (UC) - - GB002: TORREY Phase 2 trial activated in patients with pulmonary arte Exhibit 99.1 Gossamer Bio Announces Third Quarter 2020 Financial Results and Provides Corporate Update - GB004: SHIFT-UC Phase 2 trial enrolling patients with active ulcerative colitis (UC) - - GB002: TORREY Phase 2 trial activated in patients with pulmonary arterial hypertension (PAH) - - GB1275: Two posters with data from ongoing Phase 1/2 KEYNOTE-A36 clinical trial in advanced solid tumors pres
November 10, 2020	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission File Number: 001-387
October 13, 2020	EX-99.2	Datamonitor, open source medical claims, internal analysis. A High Unmet Need Remains for Patients with Uncontrolled Severe Asthma 1.2-1.5 mm Total Patients (US) ~85-90% ~10-15% Uncontrolled GINA 4/5 Patients With High Eos. Injectable biologics (Inc. GB001 Phase 2 Clinical Trial Topline Results October 13, 2020 Exhibit 99.2 This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding the potential for the LEDA Study results to allow for the design of a well-powered Phase 3 program for GB001 and our plans to discuss such results wit
October 13, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2020 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission Fil
October 13, 2020	EX-99.1	Gossamer Bio Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis - Primary endpoint of asthma worsening not met in LEDA Study, however consistent numeric reductions ranging from 32-35% observed across all t Exhibit 99.1 Gossamer Bio Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis - Primary endpoint of asthma worsening not met in LEDA Study, however consistent numeric reductions ranging from 32-35% observed across all three GB001 groups - - Statistically significant improvements in key secondary endpoint of time to first asthma worsening of 28% and 30% o
August 11, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2020 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission File
August 11, 2020	EX-10.2	Amendment No. 1 to License Agreement, dated May 11, 2020, by and between GB004, Inc. and Aerpio Pharmaceuticals, Inc. Exhibit 10.2 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD LIKELY BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH “[***]”. AMENDMENT NO. 1 TO LICENSE AGREEMENT This Amendment No. 1 to License Agreement (this “Amendment”), dated as of May 11, 2020 (but only effective as of the Amend
August 11, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission File Number: 001-38796 GOSSAMER BIO, INC. (
August 11, 2020	EX-99.1	Gossamer Bio Announces Second Quarter 2020 Financial Results and Provides Corporate Update - GB001: Phase 2 studies, LEDA in eosinophilic asthma and TITAN in chronic rhinosinusitis, on track for topline data readout in the second half of 2020 - - GB0 Exhibit 99.1 Gossamer Bio Announces Second Quarter 2020 Financial Results and Provides Corporate Update - GB001: Phase 2 studies, LEDA in eosinophilic asthma and TITAN in chronic rhinosinusitis, on track for topline data readout in the second half of 2020 - - GB002: Expected to commence Phase 2 TORREY study in pulmonary arterial hypertension in the second half of 2020 - - GB004: Expected to commen
July 2, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2020 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission File Nu
July 2, 2020	EX-10.1	Second Amendment to Credit, Guaranty and Security Agreement, dated July 2, 2020, by and among the Registrant, GB001, Inc., GB002, Inc. and GB004, Inc., as co-borrowers, the other guarantors from time to time party thereto and MidCap Financial Trust, as Agent and as a Lender and the additional lenders from time to time party thereto. Exhibit 10.1 SECOND aMENDMENT TO CREDIT, GUARANTY AND SECURITY AGREEMENT This SECOND AMENDMENT TO CREDIT, GUARANTY AND SECURITY AGREEMENT (this “Agreement”) is made as of this 2nd day of July, 2020 (“Effective Date”), by and among GB001, INC., a Delaware corporation (“GB001”), GOSSAMER BIO, INC., Delaware corporation (“Parent”), GB002, INC., a Delaware corporation (“GB002”), GB004, INC., a Delawar
June 18, 2020	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2020 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission File N
June 9, 2020	SC 13G/A	GOSS / Gossamer Bio, Inc. / BlackRock Inc. Passive Investment us38341p1021060920.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) GOSSAMER BIO, INC. - (Name of Issuer) Common Stock - (Title of Class of Securities) 38341P102 - (CUSIP Number) May 31, 2020 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic
May 21, 2020	EX-99.2	Gossamer Bio Announces Pricing of Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2027 Exhibit 99.2 Gossamer Bio Announces Pricing of Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2027 SAN DIEGO—(BUSINESS WIRE)— May 19, 2020 – Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today ann
May 21, 2020	EX-1.1	Underwriting Agreement, dated May 18, 2020, related to the Common Stock Exhibit 1.1 GOSSAMER BIO, INC. (a Delaware corporation) 9,433,963 Shares of Common Stock UNDERWRITING AGREEMENT Dated: May 18, 2020 GOSSAMER BIO, INC. (a Delaware corporation) 9,433,963 Shares of Common Stock UNDERWRITING AGREEMENT May 18, 2020 BofA Securities, Inc. SVB Leerink LLC as Representatives of the several Underwriters named in Schedule A hereto c/o BofA Securities, Inc. One Bryant Park N
May 21, 2020	EX-99.1	Gossamer Bio Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2027 Exhibit 99.1 Gossamer Bio Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2027 SAN DIEGO—(BUSINESS WIRE)— May 18, 2020 – Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today annou

GOSS / Gossamer Bio, Inc. - SEC 보고서, 연례 보고, 기업 사업 설명서

기본 통계

SEC Filings

SEC Filings (Chronological Order)

How Much do you Like Fintel?

Write a Review and get 25% Off Your Next Purchase

How can we Improve?

Other Listings